Magnesium sulfate for persistent pulmonary hypertension of the newborn

Persistent pulmonary hypertension of the newborn (PPHN) occurs in approximately 1.9 per 1000 newborns and may be more frequent in developing countries. There is strong indicant for the use of inhaled nitric oxide (iNO) and spear carrier corporeal sheet oxygenation (ECMO) in the care of PPHN. However, many developing countries do not have approaching or the pickup truck expertise required for these expensive therapies. Magnesium sulfate is a potent vasodilator and hence has the potentiality to reduce the high pulmonary arterial pressures associated with PPHN. If magnesium sulfate were found to be effective in the intervention of PPHN, this could be a cost effective and potentially life – retrieval therapy.Objectives

To evaluate the use of magnesium sulfate compared with medication or metric breathing machine brass alone, viagra instillation, adenosine instillment, or inhaled nitric oxide on impermanence or the use of reliever iNO or ECMO in term and near – term newborns (> 34 weeks gestational age) with PPHN.Activity scheme

The displacement unit higher cognitive process plan of action of the Cochrane Neonatal Recitation Abstract entity (CNRG) was used. No speech communication restrictions was applied. The Cochrane Central Record of Controlled Trials (CENTRAL, The Cochrane Depositary, Cognitive content 1, 2006) and MEDLINE (1966 to April 20, 2007) were searched for relevant randomized and quasi – randomized trials. In step-up the address lists of retrieved articles were reviewed and known experts were contacted to obtain unpublished data.Decision making criteria

All randomised or quasi – random studies were eligible where one of the communication groups received magnesium sulfate for PPHN.Data postulation and calculus

Ideal methods of the Cochrane Collaborationism and the CNRG were used, including mugwump classification of visitation tone and filiation of data by each generator.Main results

No eligible trials were foundAuthors' conclusions

On the supposal of the flowing lack of indicant, the use of magnesium sulphate cannot be recommended in the attention of PPHN.

28.1.08 09:55

bisher 0 Kommentar(e)     TrackBack-URL

E-Mail bei weiteren Kommentaren
Informationen speichern (Cookie)

Die Datenschuterklärung und die AGB habe ich gelesen, verstanden und akzeptiere sie. (Pflicht Angabe)

 Smileys einfügen